CareMed®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the treatment of adults with symptomatic obstructive ...

Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...

The FDA has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...

A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure whether patients actually feel better.

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

Cytokinetics is a late-stage biopharmaceutical company targeting muscle function. Its stock has gained almost 30% this year, besting the S&P 500. It recently celebrated a big win in China, but legal ...

Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, announced it has been awarded a $4.5 million phase IIB Bridge Award from the National Cancer Institute’s ...

A University of Massachusetts Amherst kinesiologist has received a five-year, $2 million grant from the National Institutes of Health (NIH) to advance his research on how myosin molecules—molecular ...

JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB ...